Inhibition of poxvirus growth by Terameprocol, a methylated derivative of nordihydroguaiaretic acid

Antiviral Research

Volumn 88, Issue 3, 2010, Pages 287-295

  Pollara, Justin J ^a   Laster, Scott M ^a   Petty, Ian T D ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

Author keywords

Antiviral agent; Cell to cell spread; Cowpox virus; Poxvirus; Terameprocol; Vaccinia virus

Indexed keywords

NORDIHYDROGUAIARETIC ACID; TERAMEPROCOL; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; COWPOX VIRUS; DRUG STRUCTURE; MOUSE; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; PROTEIN SYNTHESIS; VACCINIA VIRUS; VIRION; VIROGENESIS; VIRUS INHIBITION; VIRUS MORPHOGENESIS; VIRUS TRANSMISSION;

ACTINS; ANTIVIRAL AGENTS; BIOTERRORISM; CELL LINE; CLINICAL TRIALS, PHASE I AS TOPIC; COWPOX VIRUS; HUMANS; NORDIHYDROGUAIARETIC ACID; POXVIRIDAE INFECTIONS; VACCINIA VIRUS; VIRUS ATTACHMENT; VIRUS REPLICATION;

COWPOX VIRUS; LARREA TRIDENTATA; POXVIRIDAE; VACCINIA VIRUS;

EID: 78650254596     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.09.017     Document Type: Article

References (40)

1. Arasaki K., Tani K., Yoshimori T., Stephens D.J., Tagaya M. Nordihydroguaiaretic acid affects multiple dynein-dynactin functions in interphase and mitotic cells. Mol. Pharmacol. 2007, 71:454-460.
2. Arteaga S., Andrade-Cetto A., Cárdenas R. Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid. J. Ethnopharmacol. 2005, 98:231-239.
3. Blasco R., Moss B. Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. J. Virol. 1992, 66:4170-4179.
4. Chen H., Teng L., Li J.N., Park R., Mold D.E., Gnabre J., Hwu J.R., Tseng W.N., Huang R.C. Antiviral activities of methylated nordihydroguaiaretic acids. 2. Targeting herpes simplex virus replication by the mutation insensitive transcription inhibitor tetra-O-methyl-NDGA. J. Med. Chem. 1998, 41:3001-3007.
5. Craigo J., Callahan M., Huang R.C., DeLucia A.L. Inhibition of human papillomavirus type 16 gene expression by nordihydroguaiaretic acid plant lignan derivatives. Antiviral Res. 2000, 47:19-28.
6. Cudmore S., Cossart P., Griffiths G., Way M. Actin-based motility of vaccinia virus. Nature 1995, 378:636-638.
7. De Clercq E. Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections. Clin. Microbiol. Rev. 2003, 16:569-596.
8. Doceul V., Hollinshead M., van der Linden L., Smith G.L. Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science 2010, 327:873-876.
9. Edghill-Smith Y., Golding H., Manischewitz J., King L.R., Scott D., Bray M., Nalca A., Hooper J.W., Whitehouse C.A., Schmitz J.E., Reimann K.A., Franchini G. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 2005, 11:740-747.
10. Frischknecht F., Moreau V., Röttger S., Gonfloni S., Reckmann I., Superti-Furga G., Way M. Actin-based motility of vaccinia virus mimics receptor tyrosine kinase signalling. Nature 1999, 401:926-929.
11. Gnabre J.N., Brady J.N., Clanton D.J., Ito Y., Dittmer J., Bates R.B., Huang R.C. Inhibition of human immunodeficiency virus type 1 transcription and replication by DNA sequence-selective plant lignans. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:11239-11243.
12. Gooding L.R. Antibody blockade of lysis by T lymphocyte effectors generated against syngeneic SV40 transformed cells. J. Immunol. 1979, 122:2328-2336.
13. Huggins J., Goff A., Hensley L., Mucker E., Shamblin J., Wlazlowski C., Johnson W., Chapman J., Larsen T., Twenhafel N., Karem K., Damon I.K., Byrd C.M., Bolken T.C., Jordan R., Hruby D. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53:2620-2625.
14. Hwu J.R., Tseng W.N., Gnabre J., Giza P., Huang R.C. Antiviral activities of methylated nordihydroguaiaretic acids. 1. Synthesis, structure identification, and inhibition of tat-regulated HIV transactivation. J. Med. Chem. 1998, 41:2994-3000.
15. Jordan R., Tien D., Bolken T.C., Jones K.F., Tyavanagimatt S.R., Strasser J., Frimm A., Corrado M.L., Strome P.G., Hruby D.E. Single-dose safety and pharmacokinetics of ST-246, a novel orthopoxvirus egress inhibitor. Antimicrob. Agents Chemother. 2008, 52:1721-1727.
16. Khanna N., Dalby R., Connor A., Church A., Stern J., Frazer N. Phase I clinical trial of repeat dose terameprocol vaginal ointment in healthy female volunteers. Sex. Transm. Dis. 2008, 35:577-582.
17. Khanna N., Dalby R., Tan M., Arnold S., Stern J., Frazer N. Phase I/II clinical safety studies of terameprocol vaginal ointment. Gynecol. Oncol. 2007, 107:554-562.
18. Nakamura M., Nakazawa J., Usui T., Osada H., Kono Y., Takatsuki A. Nordihydroguaiaretic acid, of a new family of microtubule-stabilizing agents, shows effects differentiated from paclitaxel. Biosci. Biotechnol. Biochem. 2003, 67:151-157.
19. Neyts J., De Clercq E. Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives. Antiviral Res. 2003, 57:25-33.
20. Oh J., Broyles S.S. Host cell nuclear proteins are recruited to cytoplasmic vaccinia virus replication complexes. J. Virol. 2005, 79:12852-12860.
21. Palumbo G.J., Buller R.M. Inhibitors of the lipoxygenase pathway specifically block orthopoxvirus replication. Virology 1991, 180:457-463.
22. Park R., Chang C.C., Liang Y.C., Chung Y., Henry R.A., Lin E., Mold D.E., Huang R.C. Systemic treatment with tetra-O-methyl nordihydroguaiaretic acid suppresses the growth of human xenograft tumors. Clin. Cancer Res. 2005, 11:4601-4609.
23. Parker S., Nuara A., Buller R.M., Schultz D.A. Human monkeypox: an emerging zoonotic disease. Future Microbiol. 2007, 2:17-34.
24. Parkinson J.E., Smith G.L. Vaccinia virus gene A36R encodes a M(r) 43-50K protein on the surface of extracellular enveloped virus. Virology 1994, 204:376-390.
25. Patel D.D., Pickup D.J. Messenger RNAs of a strongly-expressed late gene of cowpox virus contain 5'-terminal poly(A) sequences. EMBO J. 1987, 6:3787-3794.
26. Patel D.D., Pickup D.J., Joklik W.K. Isolation of cowpox virus A-type inclusions and characterization of their major protein component. Virology 1986, 149:174-189.
27. Payne L.G. Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia. J. Gen. Virol. 1980, 50:89-100.
28. Reeves P.M., Bommarius B., Lebeis S., McNulty S., Christensen J., Swimm A., Chahroudi A., Chavan R., Feinberg M.B., Veach D., Bornmann W., Sherman M., Kalman D. Disabling poxvirus pathogenesis by inhibition of Abl-family tyrosine kinases. Nat. Med. 2005, 11:731-739.
29. Roberts K.L., Smith G.L. Vaccinia virus morphogenesis and dissemination. Trends Microbiol. 2008, 16:472-479.
30. Sanderson C.M., Hollinshead M., Smith G.L. The vaccinia virus A27L protein is needed for the microtubule-dependent transport of intracellular mature virus particles. J. Gen. Virol. 2000, 81:47-58.
31. Schmelz M., Sodeik B., Ericsson M., Wolffe E.J., Shida H., Hiller G., Griffiths G. Assembly of vaccinia virus: the second wrapping cisterna is derived from the trans Golgi network. J. Virol. 1994, 68:130-147.
32. Seufferlein T., Seckl M.J., Schwarz E., Beil M., v Wichert G., Baust H., Lührs H., Schmid R.M., Adler G. Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells. Br. J. Cancer 2002, 86:1188-1196.
33. Smee D.F., Sidwell R.W., Kefauver D., Bray M., Huggins J.W. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob. Agents Chemother. 2002, 46:1329-1335.
34. Smith G.L., Law M. The exit of vaccinia virus from infected cells. Virus Res. 2004, 106:189-197.
35. Smith G.L., Vanderplasschen A., Law M. The formation and function of extracellular enveloped vaccinia virus. J. Gen. Virol. 2002, 83:2915-2931.
36. Smith G.L., Murphy B.J., Law M. Vaccinia virus motility. Annu. Rev. Microbiol. 2003, 57:323-342.
37. Tagaya M., Henomatsu N., Yoshimori T., Yamamoto A., Tashiro Y., Mizushima S. Inhibition of vesicle-mediated protein transport by nordihydroguaiaretic acid. J. Biochem. 1996, 119:863-869.
38. Tooze J., Hollinshead M., Reis B., Radsak K., Kern H. Progeny vaccinia and human cytomegalovirus particles utilize early endosomal cisternae for their envelopes. Eur. J. Cell Biol. 1993, 60:163-178.
39. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79:13139-13149.
40. Yuwen H., Cox J.H., Yewdell J.W., Bennink J.R., Moss B. Nuclear localization of a double-stranded RNA-binding protein encoded by the vaccinia virus E3L gene. Virology 1993, 195:732-744.